key: cord-0693708-eakn6sve
authors: Altschuler, Eric L.; Kast, Richard E.
title: Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COVID-19 associated adult respiratory distress syndrome (ARDS)
date: 2020-04-23
journal: Med Hypotheses
DOI: 10.1016/j.mehy.2020.109774
sha: 267150996aeff4e23ef639c4bcda66ff3e7dd3d8
doc_id: 693708
cord_uid: eakn6sve

nan

Dapsone, colchicine and olanzapine as treatment adjuncts to prevent COV-ID-19 associated adult respiratory distress syndrome (ARDS) Eric L. Altschuler This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. We have no financial or other conflicts.

A novel coronavirus (COVID-19) has caused a global pandemic. There is currently no vaccine or antiviral treatment. The most serious complication from COVID-19 is death often from acute respiratory distress syndrome (ARDS) [1] .

Neutrophils are chemotaxic to many signaling gradients, interleukin-8 (IL-8) being one. ARDS patients have elevated IL-8 in bronchoalveolar lavage fluid and other neutrophil chemoattractants are present and act in synergy with that IL-8 [2] .

Evidence points to the ability of dapsone to inhibit neutrophil chemotaxis to both Nformylmethionyl-leucyl-phenylalanine and to IL-8 via interference with neutrophils' adherence functions [3, 4] .

To work in concert and synergy with with Dapsone, we note that colchicine [5] -a drug that has been used for millennia-is also a potent neutrophil inhibitor working by inhibiting microtuble polymerization.

One risk factor for mortality identified in patients hospitalized with COVID-19 infection is elevated Il-6 levels [1] . Histamine acting through the H1 receptor is a strong positive regular of Il-6 [6] . Atypical antipsychotic medications such as olanzapine and quetiapine are particular potent H1 antagonists [7, 8] and thus we think thus could be most useful in lowering Il-6 levels.

A trial of dapsone 100 mg every 12 hours, colchicine 0.4mg daily and olanzapine 10mg daily in hospitalized but not yet ventilated patients may be warranted.

We have no financial or other conflicts.

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Bronchoalveolar fluid and plasma inflammatory biomarkers in contemporary ARDS patients

Dapsone suppresses integrin-mediated neutrophil adherence function

Metabolic, pharmacokinetic, and toxicological issues surrounding dapsone

Update on colchicine

Histamine inducesexocytosis and IL-6 production from human lung macro-phages through interaction with H1receptors

Binding of antipsychotic drugs to human brain receptors focus on newer generation com-pounds

Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression